Equillium EQ
NASDAQ EQ
$2.21 -0.01 (-0.45%)
At close: Sep 4, 2026 · 4:00 PM EDT

Equillium (EQ) Change in Receivables (2023 - 2024)

Equillium (EQ) posted quarterly Change in Receivables of -$5.0 million for Q4 2024, down 14632.35% year-over-year from N/an in Q1 2024, and down 465.99% quarter-over-quarter from -$885000.0 in Q3 2024.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Equillium (EQ) Change in Receivables (2023 - 2024) Analysis & Trends

Equillium (EQ) has reported Change in Receivables for 2 consecutive years, with -$5.0 million the latest figure, recorded in Q4 2024.

  • In Q4 2024, Change in Receivables fell 14632.35% year-over-year to -$5.0 million; the TTM figure through Dec 2024 stood at -$3.7 million (down 516.39% YoY), while the FY2024 annual figure was -$3.7 million, down 516.39% from the prior year.
  • Change in Receivables declined to -$5.0 million in Q4 2024 per EQ's latest filing, from -$885000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.3 million in Q1 2024 and bottomed at -$5.0 million in Q4 2024.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -53.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 117.58 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 31.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 37.16 Mn
10 Equillium 249.33 Mn 249.33 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -5.01 Mn
Sep 30, 2024 -885,000.00
Jun 30, 2024 846,000.00
Mar 31, 2024 1.31 Mn
Dec 31, 2023 -34,000.00
Sep 30, 2023 26,000.00
Jun 30, 2023 319,000.00
Mar 31, 2023 586,000.00